Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immuno-therapy via our innovative formulation technology. Our company focuses on the development of products for treatment of metabolic diseases and various immuno-therapies. In terms of diabetes, our lead molecules are an oral "biobetter" of liraglutide and exenatide (GLP-1) in typ...
BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immuno-therapy via our innovative formulation technology. Our company focuses on the development of products for treatment of metabolic diseases and various immuno-therapies. In terms of diabetes, our lead molecules are an oral "biobetter" of liraglutide and exenatide (GLP-1) in type II diabetes. In addition to that, we are developing a combination product of insulin+GLP1. We are also exploring the use of low dose IL-2 for early onset juvenile type I diabetes.

List your booth number for exhibitions, ask us